P.3.e.003 Effectiveness of olanzapine standard oral and orally disintegrating tablets in a 1-year European observational study

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

“…In Chartier et al’s prospective observational study, almost all patients on either ODO or SOT (95.3% on ODO, 93.7% on SOT) completed the 12-month study, showing a similarly high persistence level on the medication 32. Although the two groups did not significantly differ regarding change from baseline in the Medication Adherence Rating Scale, ODO-treated patients were significantly less adherent to their antipsychotic medications at baseline and had less insight into their illness as measured by the Scale to Assess Unawareness of Mental Disorder.…”

“…Four observational cohort studies have also compared patients taking ODO and SOT 29–32. Additionally, one observational cohort study compared ODO with standard oral therapies,13 while others compared ODO with risperidone oral solution,33 as well as intramuscular olanzapine and haloperidol 34.…”

“…Two RCTs27,28 and four prospective cohort studies29–32 compared the efficacy of ODO with SOT. Additionally, one relatively small (N = 38) retrospective open-label study utilized chronological sequential assignment of patients to ODO or SOT and used PANSS to compare the efficacy of these groups 35.…”

“…Additionally, one relatively small (N = 38) retrospective open-label study utilized chronological sequential assignment of patients to ODO or SOT and used PANSS to compare the efficacy of these groups 35. The results of these studies suggest that improvements, or maintenance of improvements, in schizophrenia symptoms seen with ODO are similar to those with SOT 27–32,35. Another study compared ODO with liquid risperidone 33.…”

“…The longest comparative study of ODO versus SOT (12 months) was conducted by Chartier et al, which evaluated the effectiveness of oral olanzapine formulations in a European cohort (Greece 38%, France 35%, and Germany 26%) of patients with schizophrenia or bipolar disorder treated in a naturalistic setting 32. Patients initially prescribed ODO were significantly younger, had a significantly shorter history of illness, and were significantly more likely to be diagnosed with bipolar disorder.…”